logo
Plus   Neg
Share
Email

Stock Alert: Y-mAbs Therapeutics Slips 7%

Shares of Y-mAbs Therapeutics Inc. (YMAB) further slipped 7% on Tuesday morning after plunging nearly 20% in extended trading Monday. The late-stage clinical biopharmaceutical company hit a roadblock after FDA refused to accept for review its investigational drug Omburtamab's Biologics License Application.

YMAB is currently trading at $38.64, down $3.06 or 7.34%, on the Nasdaq.

The company completed the submission of its Biologics License Application for Omburtamab, proposed for the treatment of pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in August this year.

However, upon preliminary review, the FDA wanted further details. The regulator refused to accept for review the Omburtamab BLA and issued a Refusal to File letter for Y-mAbs Therapeutics.

The company now targets to resubmit an amended BLA before the end of 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Intel Corp's Mobileye and self-driving delivery startup Udelv have signed a deal to launch a fully driverless delivery service in the United States by 2023. The companies plan to produce more than 35,000 Mobileye-driven Transporters by 2028. Domino's Pizza and autonomous vehicle startup Nuro are launching autonomous pizza delivery in Houston, this week. Some Domino's customers in Houston can have a pizza delivered by Nuro's R2 robot. CVS Health is now offering cost COVID-19 vaccines at select CVS Pharmacy locations in four more U.S. states as part of its ongoing effort to expand access to COVID-19 vaccines. It has now expanded the program to 51 more select locations in Arkansas, Nebraska, Iowa and Maine. It began in Washington, West Virginia, Delaware and New Mexico at 15 select locations from March 31.
Follow RTT